Open original FDA record ↗Recall record
- FDA identifier
- Z-1017-2025
- Company in FDA record
- Randox Laboratories, Limited
- FDA classification date
- Jan 23, 2025
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Lipoprotein (a) on Roche Cobas c501 with nmol/l claims does not have a 510(k) or PMA.
Source facts
- Action
- Randox Laboratories Ltd (manufacturer) extended recall to the distribution center in the USA via email on 12/20/24. The distributor will then contact the customer directly via email. Letter states reason for recall, health risk and action to take: Action to be taken: " Discontinue use of and discard any copies of Roche Cobas c501 ISA listing nmol/1 claims. " Ensure clinical results are no longer reported in nmol/1 using the Roche Cobas c501 nmol/1 claims. " Complete and return the response form 12187-QA to technical.services@randox.com within five working days. Transmission of Field Safety Notice: Send a copy of the FSN to all affected customers and to those who need to be aware within your organisation. If you have any questions or concerns please contact Randox Technical Services.
- Initiated
- 2024-12-20
- Root cause
- No Marketing Application
- Distribution
- US Nationwide distribution Including PR.
- Recall number
- Z-1017-2025
- Recall status
- Open, Classified
- CDRH record ID
- 211839
- FDA classified
- 2025-01-23
- Recall event number
- 96043